News
Laurent Pharmaceuticals Receives Approval from FDA to initiate its COVID-19 Phase 2 Clinical Trial in the United States
27 August 2020
The Phase 2 study aims to evaluate the dual antiviral and inflammation-controlling effects of the company’s LAU-7b oral drug candidate against...
Read MoreLaurent Pharmaceuticals Receives Health Canada’s Approval to Initiate COVID-19 Clinical Trial
6 May 2020
Company to test LAU-7b’s dual pro-resolving inflammation and antiviral properties against COVID-19Laurent Pharmaceuticals Inc., a Montreal-based biopharmaceutical company, today announced that...
Read MoreEVENTS
Laurent Pharmaceuticals presents data with LAU-7b in Idiopathic Pulmonary Fibrosis at the 2024 ATS International Conference, May 17-22, San Diego, CA, USA
Laurent Pharma to participate to BIO International Convention, June 3-6 2024, San Diego, CA, USA
Laurent Pharma to participate to BIO International Convention, June 5-8, 2023, Boston, MA
Laurent Pharma to participate to BIO International Convention, June 13-16, 2022 – San Diego, CA
Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022